PIKA influenza vaccine - LakeShore Biopharma
Latest Information Update: 28 Aug 2025
At a glance
- Originator Yisheng Biopharma
- Developer LakeShore Biopharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in China (Parenteral)
- 24 May 2024 YS Biopharma is now called LakeShore Biopharma
- 14 Mar 2023 Yisheng Biopharma has merged with Summit Healthcare Acquisition Corp. to form YS Biopharma